XtalPi Technology
XtalPi Inc. is a pharmaceutical technology company that focuses on digital drug development solutions, leveraging quantum mechanics and artificial intelligence to enhance the efficiency of drug research and development. Founded in 2014 by a group of quantum physicists at MIT, the company has developed its Intelligent Digital Drug Discovery and Development (ID4) platform, which integrates advanced cloud computing algorithms to aid pharmaceutical firms in critical stages of drug R&D. XtalPi offers various tools, including XtalForc for visual force field calculations, XtalVision for crystal structure predictions, and Renova for platform support of its AI research initiatives. Its comprehensive services encompass crystal structure determination, solid-state testing, small molecule drug design, and collaborations in antibody and peptide research. Based in Cambridge, Massachusetts, with additional offices in China, XtalPi has established strategic partnerships with leading international pharmaceutical companies, demonstrating the broad applicability and recognition of its innovative technologies across the pharmaceutical value chain.
Top Stages
15 past transactions
Xellar Biosystems
Seed Round in 2025
Xellar Biosystems is a biotechnology company that focuses on enhancing drug discovery and development through the integration of artificial intelligence and machine learning with extensive wet-lab experiments. Its innovative platform provides researchers with simplified models and reductionistic tools, facilitating more efficient analysis of drug testing and treatment. By combining advanced computational techniques with hands-on laboratory research, Xellar aims to accelerate the process of discovering and testing new pharmaceuticals, ultimately contributing to advancements in medical treatments.
NewDEL Biotech
Series A in 2025
NewDEL Biotech is a company focused on the development of innovative drugs targeted at tumors, utilizing advanced DNA Encoded Library technology. This approach enhances the success rate of drug discovery, offering tumor patients access to next-generation alternative medicines. In addition to its drug development efforts, NewDEL Biotech provides drug screening services and biomedical technology development, as well as consulting services. Through its commitment to advancing cancer treatment, the company aims to improve therapeutic options for patients facing challenging medical conditions.
FuChe Biotech
Seed Round in 2025
FuChe Biotech is a biotechnology startup which Empower a clear future and innovative technology.
Meta Pharmaceuticals
Venture Round in 2025
Meta Pharmaceuticals is a drug development company focused on creating innovative treatments for autoimmune diseases. The company is actively involved in the emerging field of immunometabolism, aiming to develop first-in-class drugs that address these complex conditions. By integrating artificial intelligence with biomedical research, Meta Pharmaceuticals enhances its capabilities in target discovery and validation. This approach allows for a faster and more reliable analysis of new therapeutic targets and their mechanisms of action, facilitating the translation of research findings into effective new therapies. Through its commitment to advancing treatment options for autoimmune diseases, Meta Pharmaceuticals is positioned at the forefront of drug development in this critical area of healthcare.
Merda Biopharma
Series A in 2025
Merda Biopharma is a AI-enabled drug discovery technology platform that produces small molecule drugs that helps immune metabolism.
Alternative Bio
Corporate Round in 2025
Alternative Bio is a biotechnology company focused on developing novel therapeutics targeting a previously untapped class of post-translational modifying enzymes.
Orient Biotech
Venture Round in 2025
Orient Biotech is a private biotechnology company developing innovative drugs for underappreciated modified processing enzymes.
Leman Biotech
Series A in 2024
Developer and researcher of novel tumor immunotherapy drugs intended to serve the biotechnology. The company focuses on new tumor immunotherapy drugs based on immunometabolic reprogramming & artificial intelligence (AI), its team has developed the world's first Meta 10 immune metabolism reprogramming technology and established a technology platform for the discovery, development, and production of biological macromolecular drugs and new immune cell drugs.
ReviR Therapeutics
Series A in 2024
ReviR Therapeutics is a genomics-focused company that specializes in the development of RNA therapeutics aimed at treating cancer, rare genetic disorders, and infectious diseases. The company utilizes an artificial intelligence-driven platform to enhance the discovery of novel RNA-targeting medicines, thereby facilitating the delivery of innovative therapies to a wide patient population. ReviR Therapeutics combines advanced computational techniques with its expertise in RNA biology, positioning itself as a leader in the evolving field of RNA-based therapeutics.
Leman Biotech
Seed Round in 2024
Developer and researcher of novel tumor immunotherapy drugs intended to serve the biotechnology. The company focuses on new tumor immunotherapy drugs based on immunometabolic reprogramming & artificial intelligence (AI), its team has developed the world's first Meta 10 immune metabolism reprogramming technology and established a technology platform for the discovery, development, and production of biological macromolecular drugs and new immune cell drugs.
Aoshixin
Seed Round in 2024
Aoshixin is a clock chip developer that specializes in the research and development of high-precision, high-reliability clock chips and other related products. Its goods find application in industries such as high-reliability and scientific research devices.
CytoCan
Seed Round in 2023
CytoCan Corp. is a biotechnology company dedicated to the research and development of innovative cancer treatments. The company specializes in creating multi-specific fusion protein drugs designed to target cancer cells effectively. CytoCan's approach involves identifying unmet medical needs and difficult-to-treat cancers, then using its modular platform technology to develop targeted immune therapies. These therapies utilize multispecific proteins aimed at enhancing the body's ability to combat cancer.
Meta Pharmaceuticals
Seed Round in 2022
Meta Pharmaceuticals is a drug development company focused on creating innovative treatments for autoimmune diseases. The company is actively involved in the emerging field of immunometabolism, aiming to develop first-in-class drugs that address these complex conditions. By integrating artificial intelligence with biomedical research, Meta Pharmaceuticals enhances its capabilities in target discovery and validation. This approach allows for a faster and more reliable analysis of new therapeutic targets and their mechanisms of action, facilitating the translation of research findings into effective new therapies. Through its commitment to advancing treatment options for autoimmune diseases, Meta Pharmaceuticals is positioned at the forefront of drug development in this critical area of healthcare.
PhoreMost
Series B in 2021
PhoreMost Limited is a drug discovery company based in Cambridge, United Kingdom, established in 2014. The company specializes in identifying new druggable targets for cancer and other unmet medical needs through its innovative Site-Seeker platform. This platform systematically reveals cryptic druggable sites within the human genome and connects them to therapeutic functions in a live-cell context. By utilizing functionally validated protein fragments, PhoreMost informs the design of small molecule drugs that can be developed into targeted therapies. The company collaborates with a global network of academic and industrial partners to efficiently advance novel therapies to market, aiming to reduce costs and improve accessibility for patients.
METiS Pharmaceuticals
Angel Round in 2020
Jitai Medicine (METiS) is a biotechnology company that uses artificial intelligence to drive drug delivery and drug discovery. It combines advanced technologies like artificial intelligence, machine learning, and quantum simulation to achieve more effective design of innovative delivery materials, drug candidate selection and formulation design, "programmable nucleic acid drug" development, and nucleic acid delivery design.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.